Palm coein clasification
•Download as PPTX, PDF•
67 likes•21,109 views
The document discusses the new FIGO classification system for abnormal uterine bleeding (AUB). It introduces the PALM-COEIN system which provides a standardized terminology and classification. The system categorizes AUB into structural causes (polyps, adenomyosis, leiomyoma, malignancy) and non-structural causes (coagulopathy, ovulatory dysfunction, endometrial, iatrogenic, not yet classified). It provides guidelines for evaluation and outlines the notation system for documenting multiple contributing factors to a patient's AUB. The standardized classification aims to improve management of AUB internationally through a unified terminology and focus on appropriate treatment concepts.
Recommended
Recommended
More Related Content
What's hot
What's hot (20)
Viewers also liked
Viewers also liked (19)
Similar to Palm coein clasification
Similar to Palm coein clasification (20)
More from nermine amin
More from nermine amin (20)
Recently uploaded
Recently uploaded (20)
Palm coein clasification
- 1. Abnormal Uterine Bleeding: New FIGO Classification MAHMOUD MELEIS, MD
- 2. Agenda
- 4. Waves of change In 2006, FIGO identified as the appropriate body to provide supervision & international credibility to the ongoing evaluation of new terminology In 2009, FIGO Menstrual Disorders Group was formed. FIGO World Congress of Gynecology and Obstetrics , accepted the new terminology. In 2011, the PALM-COEIN Classification System created. In 2012, PALM-COEIN system was endorsed by ACOG
- 6. Nomenclature & Classification of AUB
- 7. AUB Validated Terminology AUB: Abnormal uterine bleeding Umbrella term for both regular and irregular bleeding HMB: Heavy menstrual bleeding Excessive menstrual bleeding IMB: Inter-menstrual bleeding Occurs between clearly defined cyclic and predictable menses Acute: Heavy bleeding that is of sufficient quantity to require immediate intervention to prevent further blood loss Chronic: Heavy bleeding that is of sufficient quantity to require immediate intervention to prevent further blood loss AUB Acute AUB IMB HMB Chronic AUB IMB HMB
- 8. Chronic AUB; Bleeding from the uterine corpus that is abnormal in volume, regularity and/or timing and has been present for the majority the past 6 months
- 9. Menstrual parameters Frequency 24-38 day Frequent Normal Infrequent Regularity <20 D / 12 m Absent Regular Irregular Duration 4.5-8 days Prolonged Normal Shortened Volume 5-80 ml Heavy Normal Light Suggested “normal limits” for uterine bleeding in the mid-reproductive years Munro MG. Rev Endocr Metab Disorder (2012) 13: 225-234
- 11. Structural Abnormalities P – Polyps – scored as Present or Absent A – Adenomyosis - scored as Present or Absent L – Leiomyoma Primary level – Present or Absent Secondary level – Distinguish between submucosal (SM) & others (O) Tertiary level – Detail location/size of uterine fibroids M – Malignancy & hyperplasia
- 12. AUB-P; Polyps (8-35 %) Diagnosis: US, SIS, hysteroscopy Further sub-classification: Dimensions, location & number Pre-menopausal polyps: 64 – 88% have symptoms Present with HMB, AUB, IMB, or post-coital bleeding Symptoms do NOT correlate with number, diameter & site Post-menopausal polyps: Most are symptom free Cause for 21-28% of PMP bleeding Associated with cervical polyps in 24-27% Incidence of carcinoma varies between 0–4.8%
- 14. AUB-A; Adenomyosis Ectopic endometrial glands & stroma within the myometrium Hypertrophy & hyperplasia of surrounding myometrium Usual presentation: HMB, uterine enlargement, & dysmenorrhea
- 15. Adenomyosis Linear Striations 80% PPV 71% Accurate Heterogeneous myometrium 81% PPV 69% Accurate
- 16. Sonographic findings of Adenomyosis Dueholm et al. Best Pract Res Clin Obstet Gynaecol 2006; 20: 569 82. Color Doppler: vessels following normal course through an indistinct mass
- 18. AUB-L; Leiomyoma 1ry level: AUB-L 2ry level: Submucosal – AUB-LSM Other – AUB-LO 3ry level: Types 0-8
- 20. The three stage classification system for leiomyoma
- 21. AUB-M; Malignancy & Hyperplasia Detected based upon results of office biopsy or curettage FIGO AUB Staged only as present or absent Use existing WHO and FIGO categorization Up to 40% of patients with a biopsy diagnosis of complex hyperplasia with atypia will have a concomitant endometrial adenocarcinoma present
- 23. Non-structural Abnormalities C – Coagulopathy O – Ovulatory Dysfunction E – Endometrial I – Iatrogenic N – Not yet classified
- 24. AUB-C; Coagulopathy Prevalence: 3% of women presenting with HMB Etiologies: Von Willebrand’s disease (10%) Platelet Dysfunction Factor XI deficiency Factor X deficiency Category includes patient’s taking anti-coagulants
- 25. Coagulopathy History Screening HMB since menarche One of the following: PPH Surgical related bleeding Bleeding associated with dental work Two or more of the following: Bruising 1-2 times/month Epistaxis 1-2 times/ month Frequent gum bleeding Family history of bleeding symptoms
- 26. AUB-O; Ovulatory Dysfunction Etiology: Polycystic Ovarian Syndrome (PCOS) Hypothyroidism Hyper-prolactinemia Mental stress Obesity Anorexia Weight loss Extreme exercise Adolescence Menopausal transition
- 27. AUB-E; Endometrial It is diagnosed by exclusion Etiology: Deficiencies of local production of vasoconstrictors Endothelin-1 Prostaglandin F2a Excessive production of plasminogen activators Increased local production of vasodilators Prostaglandin E2 Prostacyclin I2 Disorders of endometrial repair (inflammation) Chlamydia
- 28. AUB-I; Iatrogenic Etiology: Breakthrough bleeding (BTB) using gonadal steroids is the major component of AUB-I : Oral contraceptives Continuous or cyclic progesterone IUD or implant related bleeding Cigarette smoking : reduces the level of steroids because of enhanced hepatic metabolism Systemic agents that interfere with dopamine metabolism : Serotonin uptake inhibitors
- 29. AUB-N; Not Yet Classified Disorders that would be identified or defined only by biochemical or molecular biology assays Arterio-venous malformations Myometrial hypertrophy Category for new etiologies Pathological conditions of lower genital tract ??
- 30. Pathway overview When a woman presents with HMB : Take a proper history Decide whether the timing, amount of blood loss and/or duration of the bleeding is out of the norm. Give it a name. Do a proper assessment/evaluation. Make a (provisional) diagnosis. Initiate treatment or referral
- 31. Guidelines for investigations Guidelines General assessment Determine ovulatory status Screening for haemostasis disorders Evaluation of endometrium Evaluation of endometrial cavity structure Myometrial assessment
- 32. Guidelines for investigations 1. General assessment Not related to pregnancy Not emanating from cervix or another location Evaluate for anaemia – Hb 2. Determine ovulatory status Predictable cyclic menses every 22-35 days 3. Screening for systemic disorders of haemostasis Structured history : 90% sensitivity Positive screen: von Willebrand factor, hematologist
- 33. Guidelines for investigations 4. Evaluation of the endometrium Endometrial sampling if risk factors are persistent TVUS - endometrial thickness 5. Evaluation of structure of endometrial cavity To identify polyps, submucous myomas TVUS is not 100% sensitive –small lesions undetectable If suboptimal –proceed to SIS or hysteroscopy 6. Myometrial assessment US and +/- hysteroscopy MRI : leiomyoma - adenomyosis
- 35. Laboratory testing for evaluating Acute AUB Laboratory Evaluation Specific Laboratory Tests • Initial laboratory testing • CBC • Blood group • Pregnancy test • Initial laboratory evaluation for disorders of hemostasis • PTT & PT • Activated partial thromboplastin time • Fibrinogen • Initial testing for von Willebrand disease • VWF antigen • Ristocetin cofactor assay • Factor VIII • Other laboratory tests to consider • TSH • Serum Fe, total Fe binding capacity, and ferritin • Liver function tests • Chlamydia trachomatis
- 36. Imaging- US TVUS Assessment of myometrium, cervix, tubes, and ovaries Endometrial Polyps Adenomyosis Leiomyomas Uterine anomalies Endometrial thickening associated with hyperplasia and malignancy
- 37. Saline infusion Sonography SIS Improves the diagnosis of intrauterine pathology - polyps and fibroids Better discrimination of location and relationship to the uterine cavity May be useful prior to hysteroscopic or laparoscopic procedure for fibroids, polyps and uterine anomalies
- 38. MRI Rarely indicated Helps mapping the exact location of fibroids in planning surgery and prior to embolization When TVS or instrumentation of the uterus (i.e. congenital anomalies) cannot be performed
- 39. Hystroscopy Direct visualization of cavitary pathology Directed biopsy (main benefit over "blind" D&C)
- 40. Notation for AUB A patient may be found to have more than one potential entity contributing to symptoms of AUB. A notation approach has been designed to enable categorization. For example, if a patient is found to have endometrial hyperplasia and ovulation dysfunction with no other abnormalities, she would be categorized as follows: AUB P0 A0 L0 M1-C0 O1 E0 I0 N0 May be abbreviated as : AUB – M,0
- 41. Notation: each case has 1 identified abnormality
- 42. Classification Categorization Single Entity Examples
- 43. Notation: >1 positive category
- 44. Classification Categorization Multiple Entity Examples
- 45. Conclusion Abnormal Uterine Bleeding FIGO nomenclature and PALM-COEIN classification
- 46. FIGO nomenclature & PALM-COEIN classification Simplified and unified terminology Allows clear focus of treatment concepts Facilitates clinical and scientific research collaboration Provides the basis to structure more effective clinical teaching
- 47. Take home massage The term DUB should be replaced by coagulopathy, endometrial & ovulatory disorders FIGO believes that the classification should be used widely in undergraduate & post-graduate education to facilitate the development of practitioners who are able to provide quality care for women with AUB
Editor's Notes
- Zabat el animation
- Add hyperlink to US, SIS